• To determine if AMD3100 is generally safe.
  

• To determine if NHL and MM patients mobilized with G-CSF (10 µg/kg QD) plus AMD3100 will have a ≥2-fold increase in circulating CD34+ cells from time 0 to 11 hours after a dose of AMD3100.
  
• To determine if NHL and MM patients who are mobilized with G-CSF (10 µg/kg QD) plus AMD3100 and transplanted with ≥5 x 10e6 cells/kg will engraft PMNs by day 12, but no later than day 21.
  
• To determine if NHL tumor cells are mobilized after either G-CSF mobilization or AMD3100 administration.
  
• To examine the pharmacokinetics and pharmacodynamics of a single dose of 240 µg/kg AMD3100 administered after 4 days of G-CSF mobilization in NHL and MM patients.
  

Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) who have undergone a cyto-reductive chemotherapy regimen protocol, who are to be autologously transplanted, and meet the inclusion/exclusion criteria are eligible to enter the study. The only change to the standard of care is the addition of AMD3100 to a G-CSF mobilization regimen on the evening prior to apheresis. Patients will undergo mobilization with G-CSF (10 µg/kg QD) and on each evening prior to apheresis will receive AMD3100 (240 µg/kg). Patients will receive G-CSF(10 µg/kg QD) in the morning followed by apheresis for up to 5 consecutive days in order to collect the target number of (≥5 x 10e6) CD34+ stem cells. All patients will be treated with high dose chemotherapy in preparation for transplantation. Patients will be transplanted with cells obtained from the G-CSF and AMD3100 mobilization regimen. Patients will be followed for durability of their transplant for 12 months following transplantation. In the event that a sufficient number of cells for transplantation are not obtained from the collection, cells may be retained and pooled for transplantation at the Investigator's discretion. The number of CD34+ cells mobilized in the peripheral blood (PB) from the time of the AMD3100 dose to just prior to apheresis and those harvested in the apheresis product will be measured. The number of apheresis sessions required to obtain ≥5 x 10e6 CD34+ cells/kg will also be measured. In addition, the mobilization of NHL tumor cells and the pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of AMD3100 will be examined. Finally, success of the transplantation will be evaluated by the time to engraftment of polymorphonuclear leukocytes (PMNs) as the primary measurement and platelets (PLTs) as the secondary measurement.